Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design.
Most advanced product of the company are treatments for glaucoma and dry eye syndrome.
Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)
Company Details
- Employees
- 52
- Founded
- -
- Address
- Parque Científico De Madrid, C/ Santiago Grisolía,2,spain
- Phone
- 34 91 804 7667
- in****@****tis.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- sylentis.com
- Keywords
- Gene Sinlencing, siRNA RNAi Drugs, Ophtalmology, Biotechnology, RNAi, R&D, Pharmaceuticals, Bioinformatics, Biotecología, Biotech, Experimental drugs, Glaucoma, Dry eye syndrome, Target Therapies, Production, eyes diseases, RNAi Clinical Trials, Ophthalmology, Licensing, Research, Drug Discovey, Rational Design.
- HQ
- Tres Cantos, Madrid
Sylentis Questions
Sylentis's helpline number is 34 91 804 7667
Sylentis's website is sylentis.com
Sylentis's LinkedIn profile is https://es.linkedin.com/company/sylentis
Sylentis has
52 employees.
View email and phone details for 52
employees at Sylentis.
Sylentis's industry is
Biotechnology Research
Sylentis's top competitors are
Laboratorios Normon,
Arthex Biotech,
Oligofastx,
Nostrum Biodiscovery,
Oryzon Genomics Sa,
Amadix,
Nanovex Biotechnologies,
Pharmamar,
Vivia Biotech,
Algenex S.l.
Sylentis's support email address is info@sylentis.com
Sylentis's categories are Biotechnology Research
Sylentis's founding year is 2006
